Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of May 20, 2026, ALNY trades at $296.14 with a market cap of $38.22B and a P/E ratio of 122.46. ALNY moved +1.41% today. Year to date, ALNY is -26.46%; over the trailing twelve months it is +0.84%. Its 52-week range spans $205.87 to $495.55. Analyst consensus is strong buy with an average price target of $452.73. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded ALNY stock?
Recent politician trading activity in ALNY includes disclosures from Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
ALNY Key Metrics
Key financial metrics for ALNY
Metric
Value
Price
$296.14
Market Cap
$38.22B
P/E Ratio
122.46
EPS
$2.39
Dividend Yield
0.00%
52-Week High
$495.55
52-Week Low
$205.87
Volume
603.28K
Avg Volume
0
Revenue (TTM)
$3.71B
Net Income
$313.75M
Gross Margin
81.77%
Congressional Trades in ALNY
Jefferson Shreve sale ALNY on May 12, 2025 (amount: $50.00K).
Recent politician trading activity in ALNY includes disclosures from Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ALNY?
Yes. Rallies tracks politician and congressional stock disclosures for ALNY, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ALNY research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ALNY. It does not provide personalized investment advice.
